Equity in Access to GU Clinical Trials: What Are the Factors That May Impact Toxicity and Efficacy? Are We Lacking Diversity in IO Trials? How Can We Solve Most Common Barriers?
By
Virtual Diversity in Cancer Care
FEATURING
Tanya Barauskas Dorff
By
Virtual Diversity in Cancer Care
FEATURING
Tanya Barauskas Dorff
Comments 0
Login to view comments.
Click here to Login
